Surrozen (SRZN) Other Non-Current Assets (2020 - 2026)
Surrozen (SRZN) posted quarterly Other Non-Current Assets of $34000.0 for Q1 2026, down 66.34% year-over-year from $101000.0 in Q1 2025, and down 95.06% quarter-over-quarter from $688000.0 in Q4 2025.
Surrozen (SRZN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Surrozen's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 66.34% year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $34000.0 (down 66.34% YoY), while the FY2025 annual figure was $688000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $34000.0, down from $688000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $904000.0 in Q1 2022, with the low at $34000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $426000.0 (2023), against an average of $522352.9.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets surged 115.62% in 2024, then plunged 90.7% in 2025.
- Surrozen's Other Non-Current Assets stood at $405000.0 in 2022, then decreased by 0.74% to $402000.0 in 2023, then jumped by 71.14% to $688000.0 in 2024, then changed by 0.0% to $688000.0 in 2025, then plunged by 95.06% to $34000.0 in 2026.
- Business Quant data shows SRZN's Other Non-Current Assets at $34000.0 in Q1 2026, $688000.0 in Q4 2025, and $64000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 635,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 635,000.00 |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 688,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 688,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 688,000.00 |
| Sep 30, 2024 | 688,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Dec 31, 2023 | 402,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 394,000.00 |
| Mar 31, 2023 | 416,000.00 |
| Dec 31, 2022 | 405,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 866,000.00 |
| Mar 31, 2022 | 904,000.00 |
| Dec 31, 2021 | 549,000.00 |
| Sep 30, 2021 | 925,000.00 |